Table I:
| Name
| Company
| Treatment
|
| Advexin (p53 tumor suppressor therapy)
| Introgen Therapeutics, Inc.
| Head and Neck Cancer
|
| Embeda (morphine extended-release with sequestered naltrexone hydrochloride)
| Alpharma Inc.
| Pain
|
| Onsolis (fentanyl) - formerly BEMA Fentanyl
| BioDelivery Sciences International, Inc.
| Pain
|
| Paliperidone palmitate Intramuscular Injection
| Elan Corporation, plc and Johnson & Johnson Pharmaceutical Research & Development, L.L.C
| Schizophrenia
|
| Kynapid (vernakalant) Intravenous Injection - formerly RSD1235
| Cardiome Pharma Corp.
| Atrial Fibrillation
|
| Multaq (dronedarone)
| Sanofi-aventis
| Atrial Fibrillation, Atrial Flutter
|
| Ustekinumab
| Centocor, Inc.
| Psoriasis
|
| OT-730
| Othera Pharmaceuticals, Inc.
| Glaucoma
|
| ATryn (antithrombin alfa)
| GTC Biotherapeutics, Inc.
| Antithrombin III Deficiency
|
| Surfaxin (lucinactant)
| Discovery Laboratories, Inc.
| Respiratory Distress Syndrome
|
| Sugammadex
| Schering-Plough Corporation
| Reversal of Nondepolarizing Muscle Relaxants
|
| Xarelto (rivaroxaban)
| Johnson & Johnson Pharmaceutical Research and Development
| Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery
|
| Actemra (tocilizumab)
| Roche
| Rheumatoid Arthritis
|
| Vimpat (lacosamide)
| UCB
| Diabetic Neuropathy, Seizures
|
| Sublinox (zolpidem) Sublingual Tablets
| Orexo and Meda AB
|
|
| Iloperidone
| Vanda Pharmaceuticals Inc.
| Schizophrenia
|
| Aquavan (fospropofol disodium) Injection
| MGI Pharma, Inc.
| Sedation
|
| Alprox-TD (alprostadil) Cream
| NexMed, Inc.
| Erectile Dysfunction
|
| Zipsor (diclofenac potassium)
| Xanodyne Pharmaceuticals, Inc.
| Pain
|
